Indications / Non-small cell lung cancer · Breast cancer · Pancreatic cancer · Colorectal cancer · Acute myeloid leukemia · Chronic myeloid leukemia · Multiple myeloma · Glioblastoma · Glioma · Neuroblastoma · Medulloblastoma · Diffuse midline glioma (DIPG) · Ependymoma · Atypical teratoid rhabdoid tumour (AT/RT) · Childhood acute lymphoblastic leukemia · Ewing sarcoma · Osteosarcoma · Rhabdomyosarcoma
Breast cancer
HR+/HER2-, HER2-low and TNBC: CDK4/6, oral SERDs, PI3K pathway and TROP2 ADCs.
AACR Annual Meeting 2026
17–22 Apr 2026, San Diego · Cancer Research 86 (7_Supplement)
All 7,489 abstracts, including clinical trial (CT) and late-breaking (LB) abstracts, have Cancer Research supplement DOIs in Crossref.
Indexed in Crossref
189 abstracts matching breast cancer from the meeting's journal supplement, fetched live from Crossref 2026-11-12 10:04 UTC. This is a keyword search, not the complete abstract book.
- 6371Enhanced therapy for triple-negative breast cancer (TNBC) using combinatorial drug delivery.Santosh K. Singh, Melad Dababneh, Brian M. Rivers, Rajesh Singh
- 1771Synergistic lethality of combination treatment with Trop2-directed antibody-drug conjugate (IMMU-132) and Apo2L/TRAIL in triple negative breast cancer (TNBC)Yonit Addissie, Yoshimi Endo Greer, Stan Lipkowitz
- 947Mammary gland architectural modulation with a natural galactagogue Asparagus racemosus (Shatavari root extract) and its impact against triple negative breast cancer (TNBC) tumorigenesisMd. Imtiazul Kabir, Robin Kumar, Lakshmi Sai Pratyusha Bugata, Komal Raina
- 2030Differential impact of metformin based prevention and therapeutic strategies on aberrant metabolic signals/ molecular signatures associated with triple negative breast cancer (TNBC) during high fat/ high fructose diet feeding.Md. Imtiazul Kabir, Robin Kumar, Lakshmi Sai Pratyusha Bugata, M. Nurul Islam et al.
- 7768Biological pathways of response to neoadjuvant chemo-immunotherapy in triple-negative breast cancer (TNBC)Nickolas Stabellini, Prerana B. Parthasarathy, Iluja Gautam, Patricia A. Rayman et al.
- 1477Lysosomal routing geometry drives immunosuppressive secretion in triple negative breast cancer.Sudhanshu Sharma, Manoj K. Mishra
- 296Evaluation of ingenane diterpenoids for BL2 triple-negative breast cancer.Pamela R. Duarte, April L. Risinger
- 6090Characterization of eIF3h as a driver of triple negative breast cancer progressionTiffany J. Rios-Fuller
- 6644Adjuvant dose-dense chemotherapy is not associated with improved recurrence-free survival in early-stage, node-negative, HER2-negative breast cancer.Jonathan Shpigelman, Tasnem Alsebai, Kathy Robinson, Aum Nimavat et al.
- 7491LPA1 antagonists as potential migrastatics for triple negative breast cancerWenjie Liu, Kelsie L. Thu, Jinqiang Hou
- 4605Brigatinib based degraders as a therapeutic strategy for triple negative breast cancerManu Khosla, Suresh Alahari, Guangdi Wang
- 6132Linking metabolic reprogramming to JAK-STAT signaling in triple-negative breast cancer brain metastasisJayshree Mishra, Narendra Kumar
- 399Cyclopamine tartrate enhances antitumor immunity and suppresses triple-negative breast cancer growth.Tianyuan Wang, Lorena Arango, Li Liu
- 7085Obscurin-PH as a chemo-sensitizer in triple-negative breast cancerKelly Griffiths, Matthew Eason, Aikaterini Kontrogianni-Konstantopoulos
- 4889Distinct tumor microbiome profiles in triple negative breast cancer compared to other breast cancer subtypes: A pilot studyYangbo Sun, Chi-Yang Chiu, Jay H. Fowke, Karen Johnson
- 1838Optimal epigenetic therapies in triple-negative breast cancer.Simone Bruno, Alexandra Indeglia, Sophia Lichterfeld, Karen M. Cichowski et al.
- 6575Investigating the role of glucocorticoid-induced leucine zipper (GILZ) in triple-negative breast cancerDevyn Aniya Hill, Jennifer B. Jacob
- 2273Obesogen co-exposure promotes triple-negative breast cancer growth via adipocyte-mediated mechanisms.Sarah M. Bernhardt, Mikella Robinson, Carrie House
- 6092STAT5 modulates STAT3 and the aggressive behaviors of triple negative breast cancerAlexandra E. Temple, Emily C. Armlin, Sarah R. Walker
- 6027
- 2029Regulation of metabolic and stress adaptation in triple-negative breast cancer.Emilia F. Carlo, Columba de la Parra, Erna Mitaishvili, Blessing Ukandu
- 3811Exploring immunomodulatory tumor-derived vaccines targeting triple negative breast cancer cellsMarcio C. Bajgelman, Karina Thomaz, Daniela Mizobuti, Susana Ramalho et al.
- 2187Direct regulation of the cancer stemness by eIF4A1 in triple-negative breast cancer.Azeezat Oluwatobiloba Osikoya, Shobhit Srivastava, David Terrero, Dayanidhi Raman
- LB071Combination of isorhapontigenin and FSP1 inhibitor suppresses triple negative breast cancer cell progressionFranklin Tran, Yvette Shteynfeld, Sydney Tsao, Hong Sun et al.
- LB315Targeting endolysosomal trafficking to overcome paclitaxel resistance in triple-negative breast cancerRajiv Pathak, Prabhash Nath Tripathi, Veronica Piedra, Chandrabose Karthikeyan et al.
- 3357CD90 knockdown alters extracellular vesicles-mediated communication driving angiogenesis and tumor-stroma crosstalk in triple-negative breast cancerLeticia Alves Fernandes, Ana C. Carreira
- 317Glucose conditions influence CAMKK2-targeted therapy sensitivity in triple-negative breast cancer of different ancestry.Elham Amini, Sree latha Aramgam, Kenisha Webb, Sean Kimbro
- 3674The impact of race/ethnicity on survival in secondary triple negative breast cancerAna Isabel Jacinto, Theresa Keegan, Qian Li, Fran Maguire et al.
- 2215Tertiary lymphoid structure score associates with unique immune profile and therapeutic response in triple negative breast cancer.Kei Kawashima, Akimitsu Yamada, Itaru Endo, Kazuaki Takabe
- 4770Molecular features of patient-derived triple-negative breast cancer models based on super-enhancer-associated transcriptional regulators and biomarkersKuniko Horie, Kazuhiro Ikeda, Satoshi Inoue
- 2575Identification and characterization of anthracycline-induced chemoimmunomodulation in triple-negative breast cancerKennedy L. Coleman, Kathleen Streeks, Mariana Makarem, Iasmim Lopes de Lima et al.
- 3258Metatranscriptomic signatures in triple negative breast cancerRoshan Kumar, Golya Shahrokhi, Shafiq Shaikh, Sunday Negedu et al.
- 4986Identification of tumor microenvironment for high infiltration of lymphocytes in triple negative breast cancerSowon Choi, Hee Jin Lee, Byung-Kwan Jeong, Hyun Je Kim
- 4846Stromal MTA1 silencing reprograms mesenchymal stem cells to suppress EMT and distant metastasis in triple-negative breast cancerAdel Zaid I Mutahar, Bharathi P Salimath
- 2817Immune checkpoint therapy induces tertiary lymphoid structures in a murine model of triple-negative breast cancerZachary D. Schrank, Benjamin G. Vincent, Jonathan S. Serody
- 362Targeting RUNX transcriptional activity reduces tumor heterogeneity and aggressiveness in triple-negative breast cancer.Natalia Brenda Fernandez, Facundo Luis Couto, María Sofía Sosa, Natalia Rubinstein
- 2293The LncRNA XIST mediates resistance to estrogen receptor beta targeted therapies in triple negative breast cancerMichael Emch, Kirsten Aspros, Matthew P. Goetz, John Hawse
- 3181Mutant p53-specific TAZ/TEAD pathway dependency as a therapeutic opportunity for triple-negative breast cancerLydia Sakala, Yining Zhang, Jin G. Park, Joshua LaBaer
- 4349Development of galectin-1 and galectin-7-specific inhibitors: Immunotherapy and molecular imaging in triple-negative breast cancerRita Nehmé, David Chatenet, Nicolas Doucet, Yves St-Pierre
- 4926Modeling the metaplastic triple negative breast cancer matrixElizabeth Martin, Katherine Hebert, Mackenzie Hawes, Thomas Cheng et al.
- 2813Targeting AHR overcomes PD-L1-driven resistance to immune checkpoint blockade in triple-negative breast cancerMinkyoung Choi, Ju Hee Kim, Han-Byoel Lee, Wonshik Han
- 4584Effects of ergosterol peroxide on proteostasis disruption in triple negative breast cancer cellsMichelle Martínez-Montemayor, Aliyah Bocachica-Adorno, Adriana Aponte-Ramos, Taotao Ling et al.
- 7009From correlation to causation: SOX11 drives a coordinated immune-suppressive network that represses antigen presentation in triple-negative breast cancerSalomat Abdulkhuseynova, Ashok Pullikuth, Lance D. Miller
- CT277IvoLoC Trial: A phase II trial evaluating the efficacy of ivonescimab in metastatic endocrine refractory HR-positive HER2-negative or triple negative invasive lobular carcinoma (ILC)Jason Mouabbi, Paula Pohlmann, Rachel Layman, Roland Bassett et al.
- 2573Identification and characterization of platinum agent-induced chemoimmunomodulation in triple-negative breast cancerMariana Makarem, Kathleen Streeks, Claudia Perez Perez, Iasmim Lopes de Lima et al.
- 1805Ancestry-dependent differences of PASK (Per-Arnt-Sim Kinase) inhibitor efficacy in triple-negative breast cancer under variable glucose conditions.Ayomide Olayiwola, Sree Aramgam, K. Sean Kimbro
- 2022Tryptophan metabolites drive ferroptosis resistance in triple-negative breast cancer cells.Jamshid Motalebzadeh, Hossein Anani, Chloe Thompson-Peach, Theresa Hickey et al.
- 3773ROR1 and PMEPA1 as combined predictive biomarkers for metastasis in triple-negative breast cancer: Multi-omics and clinical validationHao Wang, Linze Xu, Song An, Yang Liu
- 5959Therapeutic targeting of HuR using a specific small-molecule inhibitor in triple negative breast cancerArundhathi Dev J R, Ajay Gogia, Sandeep R. Mathur, Ashutosh Mishra et al.
- 4323The SPHK2 inhibitor opaganib potentiates tumor-intrinsic STING activation in triple-negative breast cancer in vitroColette R. Worcester, Amrita Mitra, Harsh B. Pathak, Shane R. Stecklein
- 457Nebivolol triggers apoptosis, ferroptosis and necroptosis in triple-negative breast cancer.Wangjia Cao, Anh Vuong, Somik Chattertjee, Tagari Samanta et al.
- 768Modeling the triple-negative breast cancer extracellular matrix in a 3d tumor scaffold.Katherine Hebert, Thomas Cheng, Sophie Dietrich, Mackenzie Hawes et al.
- 173Targeting tumoral GLI1 in triple-negative breast cancer: A novel strategy to reverse the immunosuppressive microenvironmentAidan Gray, Qiang Shen, Wanda Marini, Kiichi Murakami et al.
- 7165The role of NEK2 and AURKB on triple-negative breast cancer progressionElliott Rodriguez-Lopez, Alexandra Aquino-Acevedo, Joel Orengo-Orengo, Gretchen Albarran-Acosta et al.
- 1084Serum proteomic profiling reveals metastasis-associated molecular signatures and early systemic remodeling in triple-negative breast cancerJina Kim, Hyoyoung Kim, Sunao Tanaka, Takeo Fujii et al.
- 5909Functional characterization of specific non-coding transcripts involved in chemo-resistant triple negative breast cancerMelina J. Sedano, Barbara Yang, Subramanian Dhandayuthapani, Murali Yallappu et al.
- 945Chemoprevention of triple-negative breast cancer originating from cancer stem cells using OXPHOS inhibitorsEsra Akkus, Cemile Uslu, Mert Güngör, Beyza Şimbil et al.
- 1280Pathway-based radiosensitivity and therapeutic targeting in triple-negative breast cancer subtypes.Jaitri Joshi, Jenna Jacoby, Shan Xu, Noëlle François et al.
- 1793RAC2 as a mediator of drug resistance in triple-negative breast cancerAntonisha R. McIntosh, Ngoc Voung, Destiny Ball, Perrin Black et al.
- 5837Tolvaptan as a potential anticancer and immunomodulatory treatment for triple-negative breast cancerLaura Naldi, Zhi Huang, Brionna King, Kimberly McCarter et al.
- 5003Treg-specific inhibition of hedgehog signaling alters their function and impedes the growth of murine triple-negative breast cancerIan Miranda, Courtney Swain, Brandon J. Metge, Lalita Shevde
- 2023Tryptophan and serine metabolic axis reveals novel therapeutic vulnerabilities in triple-negative breast cancer.Jamshid Motalebzadeh, Hossein Anani, Chloe Thompson-Peach, Theresa Hickey et al.
- 3664A novel 4-herb traditional Chinese medicine formula inhibits metastasis of triple-negative breast cancerLongling Wang, Julia K.M. Lee, Judy Y.W. Chan, Zhong Zuo et al.
- 1735Expanding the therapeutic potential of TXNRD inhibitors for triple-negative breast cancerBrenna Flowers, Abigail Rullo, An Zhang, Iria Lloshi et al.
- 7652Two-way proteogenomics identifies tumor-specific, immune-visible peptides for immunotherapy development in triple-negative breast cancer.Moran Chen, Jong Min Choi, Zhiao Shi, Wenrong Chen et al.
- 5833Therapeutic targeting of adhesion receptor GPR56 for the treatment of triple-negative breast cancerYueh-Ming Shyu, Joan Jacob, Carla Godoy, Treena Chatterjee et al.
- LB241Development of breast adipose-cancer co-culture model to decipher the impact of lipid heterogeneity on triple-negative breast cancerKhudeja Salim, Elnaz Sheikh, Jorge A. Belgodere, Bridgette M. Collins Burow et al.
- 7112Understanding and overcoming resistance of triple-negative breast cancer brain metastases to RET monotherapyPhi-Long Tran, Elissa Bloom, Angelina Regua, Shivani Bindal et al.
- 2111Mapping immuno-vascular signatures to characterize blood brain barrier disruption and tumor colonization in triple negative breast cancer brain metastasis.Shruti Rodrigues, Maria Jose Godoy Calderon, Manali Patwardhan, VK Gadi
- 251Targeting cyclin K-CDK12 synergizes with ATR inhibition by limiting RPA chromatin loading in triple-negative breast cancer.Eun-Bee Choi, Sophia Podeszwa, Ah-Ram Kim, Ashwani Bahl et al.
- 2183FABP4 functions as a novel cancer stem cell marker in triple-negative breast cancer.Huiyi Feng, Jinquan Xia, Fuhua Zhong, Yinghuan Cen et al.
- 658Establishment of a novel ex vivo bone metastasis culture platform for triple-negative breast cancer.Tiina E. Kähkönen, Saif Wahid, Sangita Kushary, Debabani Roy Chowdhury et al.
- 7347Leptin-driven transcriptional reprogramming in triple-negative breast cancer: Exploring biological drivers of racial disparitiesSarabjeet Kour Sudan, Amod Sharma, Shashi Anand, Jasleen Kaur et al.
- 2239The transcobalamin receptor, CD320, is a therapeutic target for metastatic triple negative breast cancer.Joanne Tejero, Felicia Lazure, Stanislav Drapela, Eduardo Miranda et al.
- 3069Involvement of ROS species in amiloride derivative-induced lysosome-dependent cell death in triple-negative breast cancer cellsNoemi Castro, Michelle Hu, Anastasia Berg, Ruiwu Liu et al.
- 5731ID4 maintains undifferentiated and immune-evasive states in aggressive triple-negative breast cancer and represents a novel druggable vulnerabilityLautaro Rivera, Carla Toro, Juan Manuel Fernandez, Jochen Maurer et al.
- 6379Gadolinium-based nanocomposite as a theranostic agent for triple-negative breast cancer: Synergistic radiosensitization, immune modulation, and image-guided therapy.Yue Wang, Jiazhuo Yan, Yihan Xu, Zhengkun Cai et al.
- 7700Secretomic profiling of triple-negative breast cancer media using Mag-Net™ HPAntolize Deetlefs, Charne Scully, Hafiza Parkar, Andrea Ellero et al.
- 1000Stereocontrolled synthesis and evaluation of functionalized lactams as potential anti-triple-negative breast cancer agentsLeila Rahimian, Tolulope Omolekan, Ojasvi Dutta, Konstantin G. Kousoulas et al.
- 3396Triple negative breast cancer organoids derived from circulating tumor cells to advance metastatic cancer research and drug resistance studiesShian-Jiun (SJ) Shih, David HSIEH, Felix Hsieh, Hsiang-Yun Lin et al.
- 3094Targeting TUBB2B: Exploiting brain metastatic vulnerabilities in triple-negative breast cancerQingling He, Jianyang Hu, Gary M. Tse, Julia Y. Tsang et al.
- 4652Deciphering neutrophil heterogeneity to enhance therapeutic efficacy of TRAIL (Tumor necrosis factor-related apoptosis-inducing ligand) in triple negative breast cancersManjari Kundu Sil, Wenqi Wu, Lichun Ma, Stan Lipkowitz
- 988Synthesis, characterization, and biological evaluation of polyisoprenylated phosphonyl ester inhibitors on triple-negative breast cancerJoshua Kofi Ablordeppey, Kweku Ofosu-Asante, Amarender Burra, Jahnissi Odoom et al.
- LB276Exposing a vulnerability to mTOR inhibition in triple negative breast cancer by targeting NIMA related kinase 2 (NEK2)Mary Vincent, Kristen Weber-Bonk, Daniella Obidi, Ananya Jain et al.
- 7400UHRF1 as an epigenetic driver of tumorigenicity and immune evasion in triple negative breast cancerMarina Suarez Pizarro, Ahhyun Kim, Jaime-Jean De La Torre, Xiyu Chen et al.
- 3056Inhibition of oncogenic phenotypes by hexanoate in triple-negative breast cancerNahara Yupe-Muñiz, Samira B.F. Abdullah-Vargas, Oscar A. Loperena-González, Ariana S. García- López et al.
- 4837Mechanistic studies on the role of GABA type A (GABAA ) ion channel receptor in tumor invasion and metastasis in triple negative breast cancerYasmeen Ahmed, Mark Garewal, Kenneth Myers, Isabelle Mercier et al.
- LB233Protein engineering of selective MMP-9 inhibitors reveals a therapeutic strategy for triple-negative breast cancerAlireza Shoari, Alexandra Hockla, Mathew A. Coban, Ella E. Aitchison et al.
- 2110Characterizing drivers of invasiveness in basal-like triple negative breast cancer.Perrin Black, Destiny Ball, Antonisha McIntosh, Alayjha Edwards et al.
- 307Triple-negative breast cancer growth and metastasis suppression by CCN5 is mediated by Merlin/NF2 and Orai-1 molecular signatures.Inamul Haque, Gargi Maity, Jamie L. Porter, Snigdha Banerjee et al.
- 364EMT-driven alterations promote dependency on nuclear kinase VRK1 activity to synergize with immune therapy in triple negative breast cancer.Priyanka Sahu, Raymond Liu, Sergey Shmelkov, Uger Ozerdem et al.
- 396Nrf2 role in regulating kaempferol’s inhibitory action on CDKs, PD-L-1, CCL2, and TGM2 in triple-negative breast cancer cells.Sukhmandeep Kaur, Patricia Mendonca, Shubham D. Mishra, Karam F. A. Soliman
- 5563Long noncoding RNAs networks as novel master regulators of cytotoxic immune cell exhaustion in triple-negative breast cancerRaquel Sanchez, Eduardo E. Chaib Lozano, Barbara Yang, Shrikanth S. Gadad et al.
- 2054Melatonin and estradiol action on let-7 family members in triple-negative breast cancer cells.Bruna Cristine De Almeida, Kelly Pedrozo Ferreira, José Maria Soares-Júnior, Katia Candido Carvalho et al.
- 6615The smac mimetic Xevinapant increases the efficacy of radiotherapy in triple negative breast cancer but only in the presence of tumor necrosis factor alpha.Mame Daro Faye, Julie Lafontaine, Philip Wong, Cynthia Menard
- LB305CARP-1/CCAR1 is a novel regulator of triple-negative breast cancer metastasisMagesh Muthu, Sijana Dzinic, Hunter Dlugas, Seongho Kim et al.
- 4792Krüppel-like factor 8 promotes triple negative breast cancer angiogenesis and metastasis through matrix metalloproteinasesEbaa Y. Ababneh, Heng Lu, Chunjiang He, Chao Shen et al.
- 2246GLUT3 inhibition reduces metastatic potential of triple-negative breast cancer cells by modulating cell mechanics via the TEAD-VASP-Actin axis.Seeun Oh, Wonkyung Lee, Song Kim, Donghoon Yoon et al.
- 5663Chemotherapy-induced galectin-1 derives drug-tolerant persister state associated EMT in triple negative breast cancer with targetable vulnerability to ferroptosis inducers.Shagufa A. Shaikh, Kedar Sharma, Dipti Bhattacharya, Vaibhav Kothari et al.
- 3902WEE1 inhibition as a therapeutic strategy in triple-negative breast cancer: Evaluating single agent and combination activity of azenosertib in preclinical models.Catherine Lee, Alexandra Levy, Mona Abed, Heekyung Chung et al.
- 3256Identification of germline variants associated with somatic mutational profiles in triple-negative breast cancer among African American womenGuochong Jia, Jie Ping, Christine B. Ambrosone, John D. Carpten et al.
- 7138Acquired saruparib (AZD5305) resistance in BRCA1-deficient triple negative breast cancer is vulnerable to DNA damage response-targeted therapeuticsMatthew R. Jordan, Pamela S. VanderVere-Carozza, Jessica Lynn Kersey, Katherine Pawelczak et al.
- 375BRD8 chromatin regulator mediates anti-HER2 response in HR+/HER2+ breast cancer.Wei Xu, Ang Gao, Parth Khatri, Gui Ma et al.
- 3096The anti-cancer effects of silibinin through the modulation of JAK1/STAT3 signaling and inhibition of MMPs levels in triple-negative breast cancer cellsSubham D. Mishra, Patricia Mendonca, Sukhmandeep Kaur, Karam F. A. Soliman
- 3968Spatial transcriptomic features associated with response to neoadjuvant therapy in triple-negative breast cancerShiqing Liao, Teia Noel, Joseph Lownik, Pavithra Nedumaran et al.
- 7082Pseudoginsenoside F11 enhances YBX1-mediated transcriptional repression of PRPS2 to inhibit the stemness and pulmonary metastasis of triple negative breast cancerKejia Xu, Huimin Liu, Yuting Bai, Haojie Chen et al.
- 2163Triple-negative breast cancer PDX models with acquired resistance to Enhertu®: A preclinical platform to uncover mechanisms of escape.Emilie INDERSIE, Benjamin GUERRIN, Eugenie DELHORBE, Eva CYPRIEN et al.
- 967Prevention and interception of triple-negative breast cancer and its metastasis to the brain with brain-permeant L024Atieh Hajirahimkhan, Alexander D. Eremin, Elizabeth Bartom, Saktimayee M. Roy et al.
- 2348Impact of transportation infrastructure on differentially expressed miRNAs in triple negative breast cancer stages at diagnosis.Nathan Xiang, Amjila Bam, Nubaira Rizvi, Micheal Celestin et al.
- 7443Low hypoxia microenvironment and impaired T cell maturation drive immunotherapy resistance in premenopausal triple negative breast cancerVidya Prasad Nimbalkar, Snijesh V P, Anupama CE, Mahalakshmi S et al.
- 6094Caveolin-1 modulates stemness and chemosensitivity in triple negative breast cancerShreya Pokharel, Naveen Chintala Ramulu, Biplov Sapkota, Dhirendra Pratap Singh et al.
- 7139Uncovering PGRMC1-PARP interaction: A novel combination therapeutic strategy in triple-negative breast cancerMahalakshmi Vijayaraghavan, Ramadevi Subramani, Michel Rojo Amador, Kyle Nguyen et al.
- 2244Pro-metastatic kinase network inhibition to treat drug-resistant triple-negative breast cancer.Margarite Matossian, Madeline Henn Bungert, Kent Schechter, Long Chi Nguyen et al.
- 54Integrating connectivity mapping resources to prioritize and personalize drug candidates for individual triple negative breast cancer patients.Lily D. Taub, Anna Byrd, Daniel J. Clarke, Ido Diamant et al.
- 2375Stress-responsive immune microenvironment in triple-negative breast cancer among African American womenAminah M. Lawal, Fulya Koksalar Alkan, Hilmi Kaan Alkan, Ahmet Burak Caglayan et al.
- 4527Melatonin as a therapeutic agent for triple-negative breast cancer: Suppressing tumor malignancy and modulating immunity via the FAK pathwayChi-Wen Luo, Cheng-Che Wu, Mei-Ren Pan, Chung-Liang Li et al.
- 3067Short-chain fatty acids suppress invasion and clonogenic survival in triple-negative breast cancer cellsAmanda Prats-Marrero, Ariana S. García-López, Liah M. Román-Calderón, Samira B. Abdullah-Vargas et al.
- 5819PD-L1 targeted radiotherapy can reduce tumor burden and delay tumor growth in a mouse model of triple-negative breast cancerJonathan Moye, Hailey Houson, Sharmila Sridhar, Sherin James et al.
- 3443Tumor and microenvironmental co-evolution in metastatic triple-negative breast cancer during immunotherapySeongyeol Park, Manon de Graaf, Artem Lomakin, Zhicheng Ma et al.
- 4038Anti-ROR2 therapies target cancer stem cells in triple-negative breast cancerEmanuela M. Ghia, Can Huang, Rebecca A. Shatsky, George F. Widhopf et al.
- CT275ALTER: A randomized Phase II trial evaluating an upfront alternating regimen of sacituzumab-govitecan and trastuzumab-deruxtecan versus sacituzumab-govitecan alone in HER2-low metastatic triple-negative breast cancer (NCT07151586)Alexandre de Nonneville, Jean-Marie Boher, Jean-Sébastien Frenel, Gerald Bagoe et al.
- CT045Initial clinical and translational results and selection of recommended phase 2 dose (RP2D) from START-002: A Phase 1b/2 study of invikafusp alfa, a first-in-class dual T-cell agonist, in combination with sacituzumab govitecan in metastatic triple-negative or HR+/HER2- breast cancerSteven J Isakoff, Anastasia Martynova, Philippe L Bedard, Margaret E Gatti-Mays et al.
- 2852Targeting notch signaling in triple negative breast cancer with a novel adeno-associated virus-mediated therapy to enhance immunomodulationMrityunjoy Biswas, Md. Manirujjaman, Yong Ran, Samarpan Majumder et al.
- 803A spatial profiling approach to evaluating the prognostic impact of heterogeneity in the triple-negative breast cancer immune microenvironment.Prerana Sensharma, Huidan Zuo, Melanie Dawe, Megan Hopkins et al.
- 4464Repurposing nebivolol with CPI-613 for triple-negative breast cancer: Linking in-vitro synergy to in-vivo exposure.Mikayla Skillman, Airong Li, Junhyoung Park, Amir Mohammad-Gholizadeh et al.
- 2242Dual TTK/PLK1 inhibition combined with G-CSF treatment synergistically suppresses metastatic progression in triple-negative breast cancer.Sunwoong Kim, Hanyoung Kim, Sung-Dae Cho, Jaehan Lee et al.
- 1914Sequential inhibition of CDK4/6 and the mitotic kinase TTK as a potential treatment in triple-negative breast cancer cell lines.Gretchen M. Albarrán-Acosta, Janangelis López-Ramos, Magda N. Álvarez-Rodríguez, Alexandra N. Aquino-Acevedo et al.
- 1595Combining DNA methylation inhibition and STING agonist in the treatment of metastatic triple-negative breast cancerSofiane Berrazouane, Rhea Dumitrescu, Xiaoting You, Jack Su et al.
- 4321Oncolytic virus exhibits potent antitumor and immunomodulatory effects in triple-negative breast cancer using syngeneic and PDX modelsYelin KIM, Jihye B Lee, Yoonjin Cha, Keunhee Oh et al.
- LB008Tumor CTR1 and serum copper dynamics reveal a coordinated copper axis linked to high-grade triple-negative breast cancer biologyVinit C. Shanbhag, Nikita Gudekar, Muhammad Yasir, Kristyn Conrad et al.
- LB391Pre-diagnostic exposures, mutational signatures, and immune profiles in triple-negative breast cancer: An overview of the PREMISE-TN projectDeborah A. Tadesse, Clara Bodelon, Cheng Peng, Kristen D. Brantley et al.
- CT225ELEGANT: Elacestrant versus standard endocrine therapy (ET) in women and men with node-positive, estrogen receptor-positive (ER+), HER2-negative (HER2-), early breast cancer (eBC) with high risk of recurrence in a global, multicenter, randomized, open-label phase 3 studyAditya Bardia, Virginia Kaklamani, Joyce O’Shaughnessy, Peter Schmid et al.
- 6825Age-stratified therapeutic strategies targeting tumor cell subclones that drive chemoresistance and immunosuppression in triple-negative breast cancerMilos Spasic, Melissa Dolan, Adrienne Marie Parsons, Beyza Koca et al.
- 5456Multiplatform bioinformatic profiling identifies TTK and NEK2 as survival-associated drivers in triple-negative breast cancer.Alexandra N. Aquino-Acevedo, Esther M. Irizarry-Quintana, Ángel D. Colón-Burgos, Marileana Rodríguez-Ruiz et al.
- 3587Independent validation of polygenic risk scores for overall and triple-negative breast cancer among high-risk African American women.Yijia Sun, Timothy Simmons, James L. Li, Armaan Jamal et al.
- 2013Mitochondrial protein translation supports metabolic rewiring of chemo-refractory triple negative breast cancer.Mariah Joy Berner, Steven W. Wall, Mokryun L. Baek, Audra Lane et al.
- 43Epigenetic-neurotransmitter crosstalk between EZH2 and dopamine D1 receptor signaling in triple-negative breast cancer.Maciej Pietrzak, Xilal Y. Rima, Gautam Sarathy, Shivani Dhekne et al.
- 3158Pharmacokinetic and biodistribution evaluation of nebivolol and dasatinib in the 4T1 triple-negative breast cancer model: Implications for drug-drug interactionAirong Li, Mikayla Skillman, Junhyoung Park, Fatima Dagher et al.
- 7003The RKIP-HER2 axis regulates breast cancer immune evasionAnia Khachikian, Mai Ho, Benjamin Bonavida
- CT013Whole-exome sequencing tumor-informed circulating tumor DNA detection after completion of neoadjuvant treatment predicts non-pCR and distant recurrence in patients with early triple-negative breast cancer (TNBC) — Results from a sub-study of the NSABP B-59/GBG-96-GeparDouze TrialMarija Balic, Gong Tang, Priya Rastogi, Gregory Young et al.
- 2011Integrin α6β4 stimulates glucose metabolism and NAD(H) production needed to drive invasive growth of triple negative breast cancer cells.Yiming Sheng, Parvarnee A. Karimpour, Andrew Elliott, Jayla L. Fenderson et al.
- 320Targeting overexpressed TTK and NEK2 decreases early metastatic potential of triple-negative breast cancer cell lines.Alexandra N. Aquino-Acevedo, Ángel D. Colón-Burgos, Esther M. Irizarry-Quintana, Elliott Rodriguez-Lopez et al.
- 4978MHC class 1 expression and distribution of multiple immune cells in chemotherapy-naïve triple-negative breast cancers: lack of antigen-presentation can bring high TILs and good prognosis, possibly via decreased regulatory T-cell compositionMakiko Yamashita, Akira I. Hida, Naomi Gondo, Yasuyo Ohi et al.
- 1053Single-cell immune profiling reveals biomarkers of pembrolizumab response in early triple-negative breast cancerInaki Comino-Mendez, Maria Rosario Chica-Parrado, María Elena Quirós-Ortega, Ana Godoy-Ortiz et al.
- 7920Integrated proteogenomics reveals molecular predictors of recurrence beyond HER2 IHC in HER2-positive breast cancerEunjoo Lee, Seung Min Park, Kyung-Hee Kim, So-Youn Jung et al.
- 2684Androgen receptor expression negatively correlates with immune infiltration and response to immune checkpoint inhibitors in ER-positive/HER2-negative breast cancer.Jun Arima, Kohei Chida, Rongrong Wu, Takafumi Shima et al.
- 6604Aurora kinase B inhibition enhances radiation response and activates type 1 interferon signaling in triple-negative breast cancer.Meirola Amgad Endraws, Kassidy M. Jungles, Caroline Bishop, Cydnee Wilson et al.
- 4371Preclinical potential of γδ T cells in novel virus-like particle vaccines for triple-negative breast cancerArnau Solé Casaramona, Anish Ghimire, Romano Josi, Sanjana Marar et al.
- 5082Loss of androgen receptor expression in triple negative breast cancer upregulates kinesin family member C1 (KIFC1) via increased β-catenin/TCF4 signalingBenecia Jackson, Zahra Mesrizadeh, Robert Lou, Yate-Ching Yuan et al.
- 2245DNMTi in combination with PARPi inhibits aberrant Wnt/β-catenin signaling and tenasin-C pathways, cancer stemness and metastasis in triple negative breast cancer.Lora Stojanovic, Kaushlendra Tripathi, Zahra Gohari, Julia L. Rutherford et al.
- 4800Targeting CD160 as an immunotherapy approach to modulate tumor angiogenesis and improve outcomes in triple-negative breast cancerAbdel-Ilah Aziz, Maxence Mocquery-Corre, Chloé Jean, Jessica Thevenard-Devy et al.
- 1576Combination treatment of mertki and immunomodulatory chemotherapy results in cxcl9 positive macrophage reprogramming and anti tumor adaptive memory in triple negative breast cancerAlex J. Smith, Zachary Schrank, Nan Guan, Diego Pedroza et al.
- 2027ATP citrate lyase fuels lipid storage to support triple negative breast cancer chemoresistance.Katherine E. Pendelton, Mokryun L. Baek, Mariah J. Berner-Wu, Steven W. Wall et al.
- 7854Prognostic impact of gain-of-function TP53 mutations on outcomes in HER2-negative advanced gastric cancer.Jong-Ho Kim, Jwa Hoon Kim, Ji Won Lee
- 3457
- 2288Neoadjuvant treatment of ER-positive/HER2-negative breast cancer with aromatase inhibitors in sequence: Ki67 dynamics and biology shiftsKamilla Fjermeros, Julius Johannes Hettich, Stephanie Beate Geisler, Unn-Cathrin Buvarp et al.
- 1512Enhanced detection of immune and oncogenic signals in HER2-positive breast cancer by a novel data-scaling methodChole Gunadi, Cindy Hu, Qian Wang
- 3661Discovery of Spondias mombin flavonoid rutin as a novel DNA methyltransferase 1 inhibitor and potential agent to treat triple negative breast cancer in patients of West African ancestryAfees John Olanrewaju, Elyssa Fraser, Joseph Enya, Leviticus Arietarhire et al.
- 6188Decoding the archetypes and ecotypes of triple-negative breast cancer in responses to chemotherapyYun Yan, Yiyun Lin, Tapsi Kumar, Shanshan Bai et al.
- 2854Antibiotics blunt the innate immune mechanisms underlying HER2+ breast cancer therapy efficacyLily J. Parker, Payal Mitra, Nofar Erlichman, Pavani Chalasani et al.
- 6646Impact of histology subtypes (ductal, lobular, and mixed ductal/lobular) on pathological complete response (pCR) following neoadjuvant chemotherapy (NAC) and chemoimmunotherapy (NACI) for estrogen receptor low (ER-low) HER2-negative breast cancer.Kai C. Johnson, Brandon Slover, Yengeniya Gokun, Dionisia M. Quiroga et al.
- 7494Development of enhanced enhertu-resistant HER2-positive breast cancer models for ADC resistance researchHongyan Sun, Yuan Fang, Fang Zhu, Yujing Zhang et al.
- 7133Combined anti-CSF-1R and anti-TIM-3 overcome macrophage-mediated mechanisms of PARP inhibitor (PARPi) resistance in BRCA1-associated triple negative breast cancerAdam Nelson, Anita K. Mehta, Madeline G. Townsend, Daniel E. Michaud et al.
- 1442Spatial transcriptomics informed tumor purity estimation from histology slides for triple negative breast cancer.Minh-Khang Le, Vivek Pujara, I-Chuang Liao, Yuan Yuan et al.
- 136Surface engineered-NK/trastuzumab cells as a novel immunotherapy for HER2-low breast cancer.Maria Jose Godoy Calderon, Manali Patwardhan, Shruti Rodrigues, Saanvi Sethi et al.
- 531Germline HRR alterations and ancestry-related outcomes in Brazilian triple-negative breast cancer patients: A comprehensive genomic and clinical study.Rafael C. Brianese, Karina M. Santiago, Gabriel Bandeira do Carmo, Leticia S. Pimentel et al.
- 6723Multisite analysis of a deep learning model for prediction of palbociclib response in patients with ER+ HER2- advanced breast cancer.Akshat Singhal, Xiaojie Zhang, Kay T. Yeung, Trey Ideker
- 6441Safety profile of post-CDK4/6 treatments in HR+/HER2− metastatic breast cancer (mBC): A network meta-analysisMartina Pagliuca, Roberto Buonaiuto, Michelino De Laurentiis, Carmine De Angelis
- 7732A stromal-immune spatial transcriptomic signature associated with MUC4 identifies potential biomarkers of trastuzumab resistance in HER2-positive breast cancerMaria F. Mercogliano, Nadine Schrode, Kristin Beaumont, Roxana Schillaci
- 5436Spatial identification of hypoxic and normoxic dormancy hotspots predicting in her2-positive and metastatic breast cancer.Tzu-Hung Hsiao, Fan Jhen Liu, Yu-Ting Kang, Kuo Yen Huang et al.
- 4461Nebivolol exhibits cell growth inhibition in drug-resistant HR+/HER2- breast cancer and anti-tumoral synergism with abemaciclib in vitro .Chia-Ling Wu, Meghana Trivedi, Shivaani Suresh Kanna
- 2489Distinct HER2- breast cancer traits among subethnic Hispanics of South FloridaJanice Darkwah, Mira G. Spillane, Tonya Omlor, Sunwoo Han et al.
- 607Quantitative analysis of microtubule lattice damage in NF1-deficient HER2-positive breast cancer under mitotic and pharmacological stress.Eleonora Messuti, Alessia Castiglioni, Simona Rodighiero, Ambra Dondi et al.
- 6645Practice patterns impacting relative dose intensity of adjuvant capecitabine among triple negative breast cancer patients with residual disease following neoadjuvant chemotherapy.Andrea House, Pratik Thakur, Blair Hoeting, Ruth Johnson et al.
- 2798
- 1200Spatially resolved tumor-cell MHC class II shapes adaptive immunity and therapeutic response in triple-negative breast cancer.Yi Liu, Sachin Kumar Deshmukh, Thiti Susiriwatananont, Panuch Eiamprapaporn et al.
- 3527Clonal evolutionary trajectory of HER2-positive breast cancer with ERBB2 or PIK3CA mutations under neoadjuvant treatmentKang Wang, Ioannis Zerdes, Emmanouil G. Sifakis, Dimitrios Salgkamis et al.
- LB015Precision biomarkers for cdk4/6 inhibitors plus endocrine treatment inHR+/HER2-breast cancer: External validation of mechanistic and hybrid predictive models across multiple neoadjuvant trialsAlvaro Köhn-Luque, Leonard Schmiester, Vessela Kristensen
- 2094Investigating the influence of genetic background on TNBC-T cell interactions in TNBC organoids and co-cultures.Batoul Farran, Moses Kamita, Shuk Mei Wong, Sylvester Antwi et al.
- LB058Clinically actionable drug synergy drives transcriptomic and metabolic reprogramming to induce ferroptosis and apoptosis in triple negative breast cancerGokul M. Das, Chetan C. Oturkar, Junhyoung Park, Iqbal Aijaz et al.
- 7392A cancer cell-intrinsic PAR1/MALT1/PD-L1 signaling pathway drives immune evasion in triple-negative breast cancerDong Hu, Prasanna Ekambaram, Zheqi Li, Linda Klei et al.
- 6715Safety, tolerability, and early immune responses in the safety run-in of an HER2 multi-epitope vaccine combined with T-DM1 in residual HER2-positive breast cancerSaranya Chumsri, Sharmila Giri, Andy J. Ness, David W. Hillman et al.
- 57Functional pathway analysis reveals discordance between clinical HER2 status and downstream effector activation in breast cancer.Salim Arslan, Julian Schmidt, Cher Bass, Foivos Ntelemis et al.
- 7863Aspirin and celecoxib use and overall survival in ER+/HER2- metastatic breast cancer: A large real-world cohort analysis.Mostafa Eysha, Mohanad Elchouemi, Harshitha Popuri, Gaurav Periapattanam et al.
- LB171AI-based B2SC identifies pre-existing TOP2A/E2F-active populations driving resistance to T-DXd in HER2+ breast cancerSe-eun Han, Minwoo Jung, Taewoo Kim, Jaeeun Park et al.
- 2279DNA methylation-based classifier predicts SERD benefit in ESR1 wild-type HR+/HER2- breast cancerShile Zhang, Nicole Zhang, Vishnu Ramani, Tingting Jiang et al.
- 4844Gli2 regulation of EMT in TNBC invasionEmily A. Jaremba, Erik Beadle, Julie Rhoades
- LB194SIRT5 induces a metabolic switch to fuel nucleotide pools and chemoresistance in triple-negative breast cancerZuen Ren, Tiziano Bernasocchi, Kiran Kurmi, Chenxu (Vincent) Guo et al.
- 5876Soluble TNF blockade as a strategy to enhance tyrosine-kinase inhibitor response and control metastatic burden in HER2-positive breast cancerSofia Bruni, Marla Ladera, Camila Jencquel, Federico Waisberg et al.